Pages that link to "Item:Q8394"
Jump to navigation
Jump to search
The following pages link to Section 1: Introduction (from DOI: 10.1080/22221751.2020.1735265) (Q8394):
View (previous 50 | next 50) (20 | 50 | 100 | 250 | 500)- Diagnosis and clinical management of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) infection: an operational recommendation of Peking Union Medical College Hospital (V2.0) (DOI: 10.1080/22221751.2020.1735265) (Q8388) (← links)
- Section 1: Introduction (from DOI: 10.1080/22221751.2020.1735265) (Q8394) (← links)
- Section 2: Protection requirements of medical personnel (from DOI: 10.1080/22221751.2020.1735265) (Q8395) (← links)
- Section 2.1: Selection of front-line personnel (from DOI: 10.1080/22221751.2020.1735265) (Q8396) (← links)
- Section 2.2: Isolation and protection requirements (from DOI: 10.1080/22221751.2020.1735265) (Q8397) (← links)
- Section 2.3: Isolation and observation of medical personnel after close contact with SARS-CoV-2 (from DOI: 10.1080/22221751.2020.1735265) (Q8398) (← links)
- Section 3: Diagnosis and treatment of SARS-CoV-2 infected patients (from DOI: 10.1080/22221751.2020.1735265) (Q8399) (← links)
- Section 3.1: Screening criteria (from DOI: 10.1080/22221751.2020.1735265) (Q8400) (← links)
- Section 3.2: Diagnostic criteria (from DOI: 10.1080/22221751.2020.1735265) (Q8401) (← links)
- Section 3.3: Examination routines of SARS-CoV-2 infected patient (from DOI: 10.1080/22221751.2020.1735265) (Q8402) (← links)
- Section 3.3.1: Screening cases on the day of visit (from DOI: 10.1080/22221751.2020.1735265) (Q8403) (← links)
- Section 3.3.2: Sequential examination of confirmed patients (from DOI: 10.1080/22221751.2020.1735265) (Q8404) (← links)
- Section 3.4: Place of treatment according to the severity of the disease (from DOI: 10.1080/22221751.2020.1735265) (Q8405) (← links)
- Section 3.4.1: Severe type (from DOI: 10.1080/22221751.2020.1735265) (Q8406) (← links)
- Section 3.4.2: Critically ill type (from DOI: 10.1080/22221751.2020.1735265) (Q8407) (← links)
- Section 3.5: Treatment (from DOI: 10.1080/22221751.2020.1735265) (Q8408) (← links)
- Section 3.5.1: General treatment (from DOI: 10.1080/22221751.2020.1735265) (Q8409) (← links)
- Section 3.5.2: Oxygen therapy (from DOI: 10.1080/22221751.2020.1735265) (Q8410) (← links)
- Section 3.5.2.1: Choice of oxygen therapy (from DOI: 10.1080/22221751.2020.1735265) (Q8411) (← links)
- Section 3.5.2.2: The way of respiratory support (from DOI: 10.1080/22221751.2020.1735265) (Q8412) (← links)
- Section 3.5.3: Antiviral treatment (from DOI: 10.1080/22221751.2020.1735265) (Q8413) (← links)
- Section 3.5.4: Glucocorticoid therapy (from DOI: 10.1080/22221751.2020.1735265) (Q8414) (← links)
- Section 3.5.5: Intravenous immunoglobulin (from DOI: 10.1080/22221751.2020.1735265) (Q8415) (← links)
- Section 3.5.6: Empirical antimicrobial therapy (from DOI: 10.1080/22221751.2020.1735265) (Q8416) (← links)
- Section 4: Protection and transfer (from DOI: 10.1080/22221751.2020.1735265) (Q8417) (← links)
- Section 5: Criteria of isolation release and discharge (from DOI: 10.1080/22221751.2020.1735265) (Q8418) (← links)
- Disclosure statement (from DOI: 10.1080/22221751.2020.1735265) (Q8419) (← links)